fondaparinux then oncology drugs

I know they have Fondaparinux due for FDA approval...which if approved should deliver healthy cash flows but looking a little further ahead they have HyAct anti-bodies which are used to target chemotherapy agents to tumours.

HA-Irinotecan will be in phase III trials this year and effectively delivers 2-4 times more drug to tumour.Main component is Hyluronic acid which is already approved for human use.This may actually turn out to be the main play for them.

SP is incredibly depressed at this stage of the game with less than 6mth,s to possible approval for Fondaparinux and maybe 18mth's for HA-Irinotecan.

Big pharma is one of the few sectors publically looking for acquisitions and new discoveries to patent to maintain their grip on the world medicinal drugs and the biggest of these are oncology drugs.

While the focus on HC might be the next mining spec..it should be a good year for the better biospecs.